UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Mayo Clinic proceedings, ISSN 0025-6196, 2015, Volume 90, Issue 8, pp. 996 - 1000
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Drug Costs | United States - epidemiology | Neoplasms - economics | Humans | Patient Participation | Patient Advocacy | Antineoplastic Agents - economics | Neoplasms - epidemiology | Prescription Fees | Neoplasms - drug therapy | Antimitotic agents | Cancer patients | Patient outcomes | Economic aspects | Dosage and administration | Drug therapy | Antineoplastic agents | Index Medicus | Abridged Index Medicus
Journal Article
2006, Counseling and Psychotherapy Transcripts, Volume 1, ISBN 1412910072, xi, 617
Book
The lancet oncology, ISSN 1470-2045, 2014, Volume 15, Issue 10, pp. 1090 - 1099
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Prognosis | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Antibodies, Monoclonal - therapeutic use | Male | Neoplasm Recurrence, Local - mortality | Patient Selection | Dose-Response Relationship, Drug | Aged, 80 and over | Adult | Female | Pyrazoles - adverse effects | Drug Administration Schedule | Administration, Oral | Pyrimidines - administration & dosage | Kaplan-Meier Estimate | Rituximab | Survival Rate | Treatment Outcome | Neoplasm Recurrence, Local - diagnosis | Disease-Free Survival | Maximum Tolerated Dose | Pyrazoles - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - adverse effects | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - mortality | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Antibodies, Monoclonal, Murine-Derived - adverse effects | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Leukemia, Lymphocytic, Chronic, B-Cell - diagnosis | Antimitotic agents | Monoclonal antibodies | Safety and security measures | Antineoplastic agents | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 1, pp. 57 - 66
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Recurrence | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - pathology | Age Factors | United States | Humans | Middle Aged | Salvage Therapy | Drug Resistance, Neoplasm | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Young Adult | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Time Factors | Antineoplastic Agents - adverse effects | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - mortality | Antibodies, Bispecific - administration & dosage | Adult | Female | Drug Administration Schedule | Europe | Kaplan-Meier Estimate | Hematopoietic Stem Cell Transplantation | Treatment Outcome | Remission Induction | Antibodies, Bispecific - therapeutic use | Disease-Free Survival | Antibodies, Bispecific - adverse effects | Adolescent | Intention to Treat Analysis | Aged | Infusions, Intravenous | T cells | Adults | Safety and security measures | Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 08/2016, Volume 375, Issue 8, pp. 740 - 753
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Humans | Middle Aged | Sialic Acid Binding Ig-like Lectin 2 - antagonists & inhibitors | Male | Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality | Remission Induction | Young Adult | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Intention to Treat Analysis | Survival Analysis | Adult | Female | Aged | Care and treatment | Usage | Acute lymphocytic leukemia | Diagnosis | Research | Patients | Health aspects | Antibody-drug conjugates | Acute lymphatic leukemia | Calicheamicin | Liver diseases | Leukemia | Minimal residual disease | Lymphatic leukemia | Survival | Clinical outcomes | CD22 antigen | Chemotherapy | Motivation | Medical prognosis | Remission | Index Medicus | Abridged Index Medicus
Journal Article
European urology, ISSN 0302-2838, 03/2020, Volume 77, Issue 3, pp. 320 - 330
Journal Article
Blood, ISSN 0006-4971, 2009, Volume 114, Issue 5, pp. 957 - 964
Life Sciences & Biomedicine | Hematology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Antibodies, Neoplasm - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Male | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Chromosomes, Human, Pair 17 - genetics | Chromosomes, Human, Pair 17 - ultrastructure | Antimetabolites, Antineoplastic - administration & dosage | Antibodies, Monoclonal, Humanized | Aged, 80 and over | Adult | Female | Retrospective Studies | Chromosome Deletion | Antibodies, Monoclonal, Murine-Derived | Rituximab | In Situ Hybridization, Fluorescence | Survival Rate | Treatment Outcome | Alemtuzumab | Antibodies, Neoplasm - administration & dosage | Disease Progression | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - mortality | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Index Medicus | Abridged Index Medicus | Clinical Trials and Observations
Journal Article
The lancet oncology, ISSN 1470-2045, 2014, Volume 15, Issue 1, pp. 48 - 58
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Pyrazoles - therapeutic use | Humans | Male | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Agammaglobulinaemia Tyrosine Kinase | Pyrimidines - adverse effects | Aged, 80 and over | Female | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - mortality | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Protein-Tyrosine Kinases - antagonists & inhibitors | Pyrazoles - adverse effects | Aged patients | Care and treatment | Lymphomas | Index Medicus
Journal Article